Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Covidien Aims To Breathe Life Into Respiratory Biz With Ventilation Pipeline

This article was originally published in The Gray Sheet

Executive Summary

Covidien plans to reinvigorate its respiratory business by targeting higher-growth market segments, such as devices to combat ventilator-associated pneumonia, the company said during its Sept. 10 investor day in New York
Advertisement

Related Content

Covidien endotracheal tube helps prevent pneumonia
Covidien endotracheal tube helps prevent pneumonia
Covidien Device Sales Grow 10% In Q4, But Respiratory Still Faces Headwinds
Covidien Device Sales Grow 10% In Q4, But Respiratory Still Faces Headwinds
Covidien-CardioDigital deal
CMS Fields Comments On Who Should Have Bariatric Surgery For Diabetes
Covidien Enters Biologic Tissue Implant Market Via $80 Mil. TSL Acquisition
Covidien To Co-Promote Allergan Lap-Band In Face Of Increased Competition
Covidien Faces Challenge Of Accelerating Growth After Spin-Off From Tyco
Advertisement
UsernamePublicRestriction

Register

MT026563

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel